Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the AAD 2017 Annual Meeting

Viamet Pharmaceuticals, Inc. today announced that the results from RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation), its Phase 2b clinical trial of VT-1161 in approximately 260 patients with onychomycosis of the toenail, will be presented in a late-breaking research forum at the American Academy of Dermatology 2017 Annual Meeting, to be held March 3-7, 2017, in Orlando, Florida. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally-administered inhibitor of fungal CYP51.